A recent regulatory filing has disclosed that Michael B. McCallister, a director at Zoetis Inc. (NYSE:ZTS), acquired 3,000 shares of common stock on May 11, 2026. The purchase was executed at prices ranging from $77.72 to $77.80 per share, representing a total investment of $233,273.
The timing of this acquisition is significant given the recent performance of ZTS stock. At the time of the filing, the stock was trading at $76.95, which is near its 52-week low of $75.11. This follows a period of intense downward pressure, with the stock experiencing a sharp decline of 32% over the preceding week. Despite this recent volatility, some analytical assessments suggest the stock may be undervalued, citing a Fair Value estimate of $155.43.
Transaction Details and Ownership Structure
The shares acquired by Mr. McCallister were purchased indirectly via the Michael and Charlene McCallister Family Trust, an entity established on November 14, 2014, which serves both Mr. McCallister and his spouse. Following this latest transaction, his indirect holdings through this specific trust amount to 24,524 shares.
Mr. McCallister's total interest in Zoetis is composed of several different holdings:
- Direct Ownership: 1,209 shares of Zoetis common stock held directly by Mr. McCallister.
- Indirect Holdings (Family Trust): 24,524 shares held through the Michael and Charlene McCallister Family Trust.
- Indirect Holdings (Revocable Trust): 6,160 shares held via the Charlene McCallister Revocable Trust, where his spouse serves as a beneficiary, settlor, and trustee.
Recent Financial Performance and Market Context
The insider purchase follows a period of mixed financial results for Zoetis Inc. The company's first-quarter 2026 earnings report indicated that the firm fell short of analyst expectations regarding profitability. Zoetis reported adjusted earnings per share (EPS) of $1.53, which missed the forecasted $1.62 by 5.6%. While revenue met expectations at $2.3 billion, the earnings miss has been a point of focus for market observers.
Financial analysts have responded to these developments with caution. Stifel recently adjusted its outlook for Zoetis, lowering its price target from $130 down to $105 while maintaining a Hold rating. A primary driver for this adjustment was the company's adjusted operational revenue growth, which reportedly lagged approximately 700 basis points behind the Street’s estimate of 2%.
The combination of missing earnings targets and lower-than-expected operational revenue growth has highlighted challenging market conditions for the company. These factors have contributed to a more cautious sentiment among investors and analysts regarding the stock's immediate trajectory.